0000899243-22-002866.txt : 20220121 0000899243-22-002866.hdr.sgml : 20220121 20220121160536 ACCESSION NUMBER: 0000899243-22-002866 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220119 FILED AS OF DATE: 20220121 DATE AS OF CHANGE: 20220121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WILLIAMS DOUGLAS E CENTRAL INDEX KEY: 0001184847 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39615 FILM NUMBER: 22545979 MAIL ADDRESS: STREET 1: C/O AMGEN INC STREET 2: ONE AMGEN CENTER DR CITY: THOUSAND OAKS STATE: CA ZIP: 91320-1799 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Codiak BioSciences, Inc. CENTRAL INDEX KEY: 0001659352 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 CAMBRIDGEPARK DRIVE STREET 2: SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-949-4100 MAIL ADDRESS: STREET 1: 35 CAMBRIDGEPARK DRIVE STREET 2: SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02140 FORMER COMPANY: FORMER CONFORMED NAME: Codiak Biosciences, Inc. DATE OF NAME CHANGE: 20151125 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-01-19 0 0001659352 Codiak BioSciences, Inc. CDAK 0001184847 WILLIAMS DOUGLAS E C/O CODIAK BIOSCIENCES, INC. 35 CAMBRIDGEPARK DRIVE, SUITE 500 CAMBRIDGE MA 02140 0 1 0 0 President & CEO Stock Option (Right to Buy) 7.21 2022-01-19 4 A 0 200000 0.00 A 2032-01-18 Common Stock 200000 200000 D Restricted Stock Units 2022-01-19 4 A 0 41000 0.00 A Common Stock 41000 41000 D 25% of this option shall vest and become exercisable on January 19, 2023, with the remainder vesting in 12 equal quarterly installments thereafter. Each restricted stock unit represents a contingent right to receive one share of common stock. On January 19, 2022, the reporting person was granted 41,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. /s/ Yalonda Howze, Attorney-in-Fact for Douglas E. Williams 2022-01-21